Bayer enters cancer research deal with Compugen

FRANKFURT/JERUSALEM (Reuters) - German pharmaceuticals company Bayer AG has entered a new cancer partnership with Israel's Compugen Ltd to research, develop and commercialise antibody-based therapies. The agreement sent Compugen's shares up more than 50 percent. The two partners will jointly carry out a preclinical research programme, they said in a statement on Monday. Under the deal, Compugen will receive an upfront payment of $10 million, and is eligible to receive over $500 million in potential milestone payments. ...



via Health News Headlines - Yahoo! News http://news.yahoo.com/bayer-enters-cancer-research-deal-compugen-133605914.html